Inventor

TSURUSHITA NAOYA

US50 patents

⚠️ This page may combine multiple inventors who share the name “TSURUSHITA NAOYA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

TSURUSHITA NAOYA

JN BIOSCIENCES LLC

Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece

Hybrid constant regions

Antibodies to TIGIT

Hybrid constant regions

Multimeric hybrid Fc proteins for replacement of IVIG

Bifunctional molecules for treatment of immune disorders

Bispecific antibodies which bind PD-L1 and GITR

Antibodies to TIGIT

PDL BIOPHARMA INC

Alteration of Fc-fusion protein serum half-lives by mutagenesis

Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Anti-CCR5 antibody

Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Amphiregulin antibodies and their use to treat cancer and psoriasis

Humanized antibodies to gamma-interferon

UNIV TEXAS

Anti-OX40 antibodies and methods of using the same

Nucleic acid encoding anti-OX40 antibodies

Anti-OX40 antibodies and methods of using the same

Anti-OX40 antibodies and methods of using the same

KUMAR SHANKAR

Humanized anti-α 9 integrin antibodies and the uses thereof

Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof

Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof

Generation, expression and characterization of the humanized K33N monoclonal antibody

LIU YONG-JUN

Anti-OX40 antibodies and methods of treating cancer

Anti-OX40 antibodies and methods of using the same

LILLY CO ELI

Humanized anti-βantibodies

Humanized antibodies that sequester amyloid beta peptide

FACET BIOTECH CORP

Alteration of Fc-fusion protein serum half-lives by mutagenesis

Tethered vectors for cell surface immunoglobulin display

LIVTECH INC

Anti-human TROP-2 antibody having an antitumor activity in vivo

Anti-hDlk-1 antibody having an antitumor activity in vivo

TSO J YUN

Antibodies to CD122

Hybrid constant regions

PROGENICS PHARM INC

Anti-CCR5 antibody

Anti-CCR5 antibody

PROTEIN DESIGN LABS INC

Humanized antibodies to γ-interferon

UNIV WASHINGTON

Humanized antibodies that sequester abeta peptide

GENETICS INSTITUE LLC

Antibodies against CTLA4

MA DANGSHE

Antibodies for the treatment of Clostridium difficile-associated infection and disease

CHANG MING-SHI

Humanized anti-IL-20 antibody and uses thereof

HOLTZMAN DAVID M

Humanized antibodies that sequester amyloid beta peptide

AKAMATSU YOSHIKO

Mammalian cell-based immunoglobulin display libraries

ABBOTT BIOTHERAPEUTICS CORP

Treatment of inflammatory bowel diseases with anti-IP-10 antibodies

CELLERANT THERAPEUTICS INC

Humanized anti-CLL-1 antibodies

LIVTECH INC & MDASH TEIKYO UNIVERSITY BIOTECHNOLOGY RES CT

Anti-hDlk-1 antibody having an antitumor activity in vivo

CHIOME BIOSCIENCE INC

Anti-human TROP-2 antibody having an antitumor activity in vivo

TSURUSHITA NAOYA

Expression vectors

HINTON PAUL R

Alteration of Fc-fusion protein serum half-lives by mutagenesis

UNIV NAT CHENG KUNG

Humanized anti-IL-20 antibody and uses thereof

PINTEON THERAPEUTICS INC

Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies